Number of reportable segments not reported.

No definition available.

Name:	qnrx_NumberOfReportableSegmentsNotDisclosedFlag
Namespace Prefix:	qnrx_
Data Type:	xbrli:booleanItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development pursuant to external clinical development.

+ References

No definition available.

+ Details

Name:	qnrx_ResearchAndDevelopmentExpenseExternalClinicalDevelopment
Namespace Prefix:	qnrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development pursuant to personnel related and stock-based compensation.

+ References

No definition available.

+ Details

Name:	qnrx_ResearchAndDevelopmentExpensePersonnelRelatedAndStockBasedCompensation
Namespace Prefix:	qnrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-18

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=qnrx_SingleReportableSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Operating Segment (Details)	3 Months Ended				6 Months Ended		9 Months Ended
	Sep. 30, 2025 USD ($)	Mar. 31, 2025	Sep. 30, 2024 USD ($)	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Sep. 30, 2025 USD ($) segment	Sep. 30, 2024 USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of operating segments \| segment							1
Number of reportable segments not reported		true		true	true	true
Total research and development expenses	$ 2,281,174		$ 1,079,620				$ 6,705,898	$ 2,552,421
Single reportable segment
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
External clinical development expenses	1,645,882		687,666				4,980,796	1,450,903
Personnel related and stock-based compensation	464,008		253,739				1,151,498	726,358
Other research and development expenses	171,284		138,215				573,604	375,160
Total research and development expenses	$ 2,281,174		$ 1,079,620				$ 6,705,898	$ 2,552,421